FilingSEC EDGAR8-K
NeOnc Technologies Schedules FDA Meeting to Discuss NEO212 Phase 2 Study
· SEC accepted
StagePhase 2 Preparation
Filing content
The company is scheduled to meet with the FDA on November 17, 2026, to seek feedback on its NEO212 clinical development program, including Phase 2 study design and potential regulatory pathways.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…